Patients With Low CsA-Sensitive Dye Efflux Are More Likely to Die Within the Next 12 Months Than Those With High CsA-Sensitive Dye Efflux
| Patient Status . | Patient Status of PBMC Samples in Which B Cells Have the Indicated % of CsA-Sensitive Dye Efflux . | |
|---|---|---|
| . | Less Than 35% . | Greater Than 35% . |
| Exposed to VAD | 6/13 (46%) | 22/50 (44%) |
| Exposed to M/P | 5/13 (38%) | 16/50 (32%) |
| Other therapy | 2/13 (15%) | 6/50 (12%) |
| Untreated | 0/13 (<7%) | 8/50 (16%) |
| Samples taken within 12 mo of death4-150 | 6/13 (46%) | 10/50 (20%) |
| Total samples | 13/63 (20%) | 50/63 (80%) |
| Patient Status . | Patient Status of PBMC Samples in Which B Cells Have the Indicated % of CsA-Sensitive Dye Efflux . | |
|---|---|---|
| . | Less Than 35% . | Greater Than 35% . |
| Exposed to VAD | 6/13 (46%) | 22/50 (44%) |
| Exposed to M/P | 5/13 (38%) | 16/50 (32%) |
| Other therapy | 2/13 (15%) | 6/50 (12%) |
| Untreated | 0/13 (<7%) | 8/50 (16%) |
| Samples taken within 12 mo of death4-150 | 6/13 (46%) | 10/50 (20%) |
| Total samples | 13/63 (20%) | 50/63 (80%) |
Patients listed as exposed to VAD received this treatment at some point in their therapy before the sample analyzed here; they may or may not also have received other types of therapy. Patients listed as exposed to M/P (melphalan/prednisone) received only M/P and had not been exposed to VAD.
This group is comprised of the same patients listed in the preceding groups.